Recently included in the 2024 new revised diagnostic criteria of Alzheimer's disease (AD),
glial fibrillary acidic protein (GFAP) has garnered significant attention. A systematic review …

The field of blood-based biomarkers for Alzheimer's disease (AD) has advanced at an
incredible pace, especially after the development of sensitive analytic platforms that can …

Objective Few studies have comprehensively examined how health and disease risk
influence Alzheimer's disease (AD) biomarkers. The present study examined the association …

Blood-based biomarkers have been extensively evaluated for their diagnostic potential in
Alzheimer's disease. However, their relative prognostic and monitoring capabilities for …

While immune function is known to play a mechanistic role in Alzheimer's disease (AD),
whether immune proteins in peripheral circulation influence the rate of amyloid-β (Aβ) …

CSF-to-plasma transition will open new avenues for molecular phenotyping of Alzheimer's
disease (AD). Here we evaluated a panel of AD biomarkers in matched CSF and plasma …

Physical activity is a promising preventative strategy for Alzheimer's disease: it is associated
with lower dementia risk, better cognition, greater brain volume and lower brain beta …

Introduction In recent years, exciting developments in disease modifying treatments for
Alzheimer's disease (AD) have made accurate and timely diagnosis of this disease a priority …

INTRODUCTION Blood biomarkers showed values for predicting future cognitive
impairment. Evidence from the community‐based cohort was limited only in high‐income …

INTRODUCTION We investigated whether novel plasma biomarkers are associated with
cognition, cognitive decline, and functional independence in activities of daily living across …